TPMT/NUDT15 pharmacogenetic testing now commissioned

TPMT and NUDT15 pharmacogenetic testing is now commissioned on the NHS for both adult and paediatric patients with Acute Lymphoblastic Leukaemia only, the updated  national genomic test directory can be found here

These pharmacogenetic tests will identify if a patient is susceptible to an increased risk of myelosuppression when treated with thiopurines, such as 6-mercaptopurine (6MP).

For adult patients the dosing guidelines can be found here. It is important to note that these guidelines give dosing recommendations for 6MP for patients aged 25 years or older only and consider only the most common TPMT/NUDT15 variants. The recommendations in the guidelines are not intended to guide the treatment of patients under 25 years, or patients enrolled in a research study and in such circumstances, clinical staff should consult the research study treatment protocol or the locally agreed treatment protocol.

If you have any questions, please contact [email protected] and [email protected] OR please contact the authors of the guidelines.

Latest News

By UK SACT Protocols Pilot Team on 20th November 2026

Have Your Say: Review the First UK SACT Protocol and Provide Feedback

Dear Colleagues working in cancer services We are writing to invite you to review and provide feedback on the first protocol produced as part of the UK SACT Protocols Pilot.…

Read article
By Mohammed Patel on 11th November 2026

UK BMT Pharmacists Group Educational Meeting – Friday 13th November 2026. Time:14:00 to 16:00

The next UK BMT Pharmacists Group Educational Meeting is on Friday 13th November, 2pm–4pm. The sessions include: Maintenance Therapy for AML After Allogeneic BMT with Dr Mili Shah, Consultant Haematologist,…

Read article
By UK SACT Board on 9th November 2026

New UK SACT Board National Intrathecal and Intraventricular SACT Guidance

Dear colleagues, We are pleased to share the newly published UK SACT Board National Guidance on the Safe Administration of Systemic Anti-Cancer Therapies via the Intrathecal or Intraventricular Routes. This…

Read article
By BOPA Executive Committee on 9th November 2026

BOPA members flying the flag for cancer pharmacy at ESMO 2026

It was fantastic to see BOPA members representing cancer pharmacy at ESMO Congress 2026 in Madrid, which brought together the global cancer community from 23 to 27 October to share…

Read article